TCRX
TScan Therapeutics, Inc.
$0.9655
-2.87%
$65.0M
No data for this timeframe.
Vol
Market Cap$65.0M
Cap SizeMicro Cap
Inst. Holders6 funds
Inst. Value$4.5M
Inst. Activity2 buys / 3 sells
SEC Reports2
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001783328·Prev Close $0.9940
Recent Activity
May 20, 2026
Insider
Gruia Gabriela sold 67,000 shares
Director @ $0.00 ($0.00)
May 20, 2026
Insider
Dorton Katina sold 67,000 shares
Director @ $0.00 ($0.00)
May 20, 2026
Insider
Klencke Barbara sold 67,000 shares
Director @ $0.00 ($0.00)
May 12, 2026
earnings_calendar
TCRX Q1 2026 Earnings Scheduled — 2026-05-12
May 6, 2026
SEC
TScan Therapeutics reported Q1 2026 revenue of $1.0M (down 55% YoY from $2.2M) and a net loss of $28.7M ($-0.22 EPS), sl
8-K — Impact 4/10
Apr 2, 2026
SEC
TScan Therapeutics announced the resignation of Leiden Dworak as Vice President of Finance and principal accounting offi
8-K — Impact 3/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
1,141,069 shares ($1.1M)
Inst.
TWO SIGMA INVESTMENTS, LP — ADD
651,179 shares ($651.2K)
Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$6.00 (Mar 2026)
Current $0.9655
Low $5.00
Median $6.00
High $7.00
4 analysts
$5.00
$7.00
Analyst Ratings
3Strong Buy
7Buy
3Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 5, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.20 ▼ -15.5% | $-0.22 — $-0.19 | 27% YoY | 4 |
| Next Q | $-0.21 ▼ -14.7% | $-0.25 — $-0.19 | 23% YoY | 4 |
| Current FY | $-0.84 ▼ -15.0% | $-0.91 — $-0.74 | 16% YoY | 4 |
| Next FY | $-0.89 ▼ -15.6% | $-1.04 — $-0.76 | -5% YoY | 4 |
Latest Reports
NEUTRAL
8-K
4/10
TScan Therapeutics reported Q1 2026 revenue of $1.0M (down 55% YoY from $2.2M) and a net loss of $28.7M ($-0.22 EPS), sl
May 6, 2026
NEUTRAL
8-K
3/10
TScan Therapeutics announced the resignation of Leiden Dworak as Vice President of Finance and principal accounting offi
Apr 2, 2026
BULLISH
Press
7/10
TScan Therapeutics reported financial results for Q4 and full-year 2025, highlighted by a 268% year-over-year increase i
Mar 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $2.5M | — |
| RENAISSANCE TECHNOLOGIES LLC | $1.1M | ADD |
| TWO SIGMA INVESTMENTS, LP | $651.2K | ADD |
| MORGAN STANLEY | $225.8K | TRIM |
| BANK OF AMERICA CORP | $38.7K | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 20, 2026 | Gruia Gabriela | A | $0.00 |
| May 20, 2026 | Dorton Katina | A | $0.00 |
| May 20, 2026 | Klencke Barbara | A | $0.00 |
| May 20, 2026 | Woods Keith | A | $0.00 |
| May 20, 2026 | Nicholson Garry | A | $0.00 |
6 institutional holders with $4.5M total value (4,533,010 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, TWO. Net selling activity: 3 institutions trimmed/exited vs 2 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,475,733 | $2.5M | 54.6% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,141,069 | $1.1M | 25.2% | ADD +37.5% |
| 3 | TWO SIGMA INVESTMENTS, LP | 651,179 | $651.2K | 14.4% | ADD +55.3% |
| 4 | MORGAN STANLEY | 225,829 | $225.8K | 5.0% | TRIM -73.4% |
| 5 | BANK OF AMERICA CORP /DE/ | 38,700 | $38.7K | 0.9% | NEAR_EXIT -82.6% |
| 6 | FMR LLC | 500 | $500.00 | 0.0% | NEAR_EXIT -95.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 829,919 | 1,141,069 | +37.5% | $1.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 419,404 | 651,179 | +55.3% | $651.2K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 847,537 | 225,829 | -73.4% | $225.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 223,024 | 38,700 | -82.6% | $38.7K | 2025-Q4 |
| FMR LLC | NEAR_EXIT | 9,993 | 500 | -95.0% | $500.00 | 2025-Q4 |
| UBS Group AG | NEAR_EXIT | 400,401 | 11,073 | -97.2% | $20.2K | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 22,171 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | ADD | 592,970 | 853,346 | +43.9% | $1.2M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 169,706 | 792,056 | +366.7% | $1.1M | 2025-Q2 |
| UBS Group AG | DOUBLED | 123,441 | 400,401 | +224.4% | $580.6K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 90,201 | 365,034 | +304.7% | $529.3K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 170,350 | 217,967 | +28.0% | $316.1K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEAR_EXIT | 112,941 | 22,171 | -80.4% | $32.1K | 2025-Q2 |
| FMR LLC | TRIM | 21,878 | 10,878 | -50.3% | $15.8K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 20,215 | 323 | -98.4% | $468.00 | 2025-Q2 |
| MORGAN STANLEY | ADD | 412,858 | 592,970 | +43.6% | $818.3K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 10,600 | 169,706 | +1501.0% | $234.2K | 2025-Q1 |
| UBS Group AG | ADD | 91,860 | 123,441 | +34.4% | $170.3K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 90,201 | — | $124.5K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 142,617 | 54,392 | -61.9% | $75.1K | 2025-Q1 |
| FMR LLC | DOUBLED | 1,450 | 21,878 | +1408.8% | $30.2K | 2025-Q1 |
| MORGAN STANLEY | ADD | 299,319 | 412,858 | +37.9% | $1.3M | 2024-Q4 |
| CITADEL ADVISORS LLC | NEW | — | 142,617 | — | $433.6K | 2024-Q4 |
| UBS Group AG | DOUBLED | 19,344 | 91,860 | +374.9% | $279.3K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 13,846 | 19,540 | +41.1% | $59.4K | 2024-Q4 |
6 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 20, 2026 | Gruia Gabriela | Director | A | 67,000 | $0.00 | $0.00 |
| May 20, 2026 | Dorton Katina | Director | A | 67,000 | $0.00 | $0.00 |
| May 20, 2026 | Klencke Barbara | Director | A | 67,000 | $0.00 | $0.00 |
| May 20, 2026 | Woods Keith | Director | A | 67,000 | $0.00 | $0.00 |
| May 20, 2026 | Nicholson Garry A | Director | A | 67,000 | $0.00 | $0.00 |
| May 20, 2026 | BAKER BROS. ADVISORS LP | Director | A | 67,000 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 3.5/10.
Historical analyst distribution (last covering-analyst action Mar 2026): 77% buy across 13 analysts — 3 strong buy, 7 buy, 3 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Mar 2026. No current recommendation available.
$6.00 mean target (Mar 2026)
$5.00 Low
$7.00 High
| Metric | Value |
|---|---|
| Current Price | $0.9655 |
| Target Low | $5.00 |
| Target Mean | $6.00 |
| Target Median | $6.00 |
| Target High | $7.00 |
| # Analysts | 4 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.20 | $-0.22 | $-0.19 | 26.8% | -15.5% | 0↑ 1↓ | $0.0B | -18.7% | 4 |
| Next Q 2026-09-30 |
$-0.21 | $-0.25 | $-0.19 | 23.2% | -14.7% | 0↑ 4↓ | $0.0B | -7.1% | 4 |
| Current FY 2026-12-31 |
$-0.84 | $-0.91 | $-0.74 | 15.8% | -15.0% | 0↑ 4↓ | $0.0B | -26.8% | 4 |
| Next FY 2027-12-31 |
$-0.89 | $-1.04 | $-0.76 | -5.3% | -15.6% | 0↑ 1↓ | $0.0B | 3.3% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.205 | |
| 7d ago | $-0.205 | |
| 30d ago | $-0.177 | -0.027 |
| 60d ago | $-0.177 | -0.027 |
| 90d ago | $-0.207 | +0.002 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 5, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 7 | 3 | 0 | 0 | 77% | |
| May 1, 2026 | 3 | 7 | 3 | 0 | 0 | 77% | |
| Apr 1, 2026 | 3 | 7 | 3 | 0 | 0 | 77% | |
| Mar 1, 2026 | 3 | 7 | 3 | 0 | 0 | 77% | |
| Feb 1, 2026 | 3 | 7 | 3 | 0 | 0 | 77% | |
| Jan 1, 2026 | 3 | 7 | 3 | 0 | 0 | 77% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings_calendar
TCRX Q1 2026 Earnings Scheduled — 2026-05-12
May 6, 2026
earnings
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><em>Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026</em></p>
May 4, 2026
earnings_calendar
TCRX Q1 2026 Earnings Scheduled — 2026-05-04
Apr 27, 2026
routine
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
<p align="justify">WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology compan
Apr 8, 2026
other
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
<p align="justify">WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology compan
Mar 11, 2026
earnings_calendar
TCRX Q4 2025 Earnings After Market Close — 2026-03-11
Mar 4, 2026
earnings
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
<p align="center"><em>Presented positive updated data from the ALLOHA</em><em>™</em><em> Phase 1 heme trial at 67</em><sup><em>th</em></sup><em> Ameri
Mar 4, 2026
earnings_calendar
TCRX Q4 2025 Earnings After Market Close — 2026-03-04